Ardelyx

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Ardelyx and other ETFs, options, and stocks.

About ARDX

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. 

CEO
Michael G. Raab
CEOMichael G. Raab
Employees
489
Employees489
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2007
Founded2007
Employees
489
Employees489

ARDX Key Statistics

Market cap
722.70M
Market cap722.70M
Price-Earnings ratio
-12.80
Price-Earnings ratio-12.80
Dividend yield
—
Dividend yield—
Average volume
5.49M
Average volume5.49M
High today
$3.02
High today$3.02
Low today
$2.84
Low today$2.84
Open price
$2.99
Open price$2.99
Volume
5.45M
Volume5.45M
52 Week high
$8.40
52 Week high$8.40
52 Week low
$2.84
52 Week low$2.84

Stock Snapshot

Ardelyx(ARDX) stock is priced at $2.85, giving the company a market capitalization of 722.7M. It carries a P/E multiple of -12.80.

As of 2026-11-07, Ardelyx(ARDX) stock has fluctuated between $2.84 and $3.02. The current price stands at $2.85, placing the stock +0.4% above today's low and -5.6% off the high.

The Ardelyx(ARDX)'s current trading volume is 5.45M, compared to an average daily volume of 5.49M.

During the past year, Ardelyx(ARDX) stock moved between $2.84 at its lowest and $8.40 at its peak.

During the past year, Ardelyx(ARDX) stock moved between $2.84 at its lowest and $8.40 at its peak.

ARDX News

Simply Wall St 1d
Ardelyx, Inc. Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Simply Wall St

...

Ardelyx, Inc. Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Simply Wall St
Simply Wall St 2d
Ardelyx Finishes Phase 3 Enrollment Early As Patent Protection Nears

Ardelyx (NasdaqGM: ARDX) completed enrollment ahead of schedule in its Phase 3 ACCEL trial of IBSRELA for chronic idiopathic constipation. The ACCEL study eval...

Ardelyx Finishes Phase 3 Enrollment Early As Patent Protection Nears
The Motley Fool 3d
Ardelyx: 3 Key Takeaways for Long-Term Investors

On its third quarter of 2026 earnings call, held on Nov. 3, 2026, Ardelyx (ARDX +8.09%) reported total product revenue of $125.5 million. Expanding patient adop...

Ardelyx: 3 Key Takeaways for Long-Term Investors

Analyst ratings

100%

of 11 ratings
Buy
100%
Hold
0%
Sell
0%

More ARDX News

Simply Wall St 5d
Does Ardelyx Look Undervalued After New XPHOZAH Data?

has seen a sharp swing in fortunes, with the share price well below its highs even as investors focus on what its kidney treatment portfolio could mean for futu...

Does Ardelyx Look Undervalued After New XPHOZAH Data?

People also own

Based on the portfolios of people who own ARDX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.